Auger M J, Mackie M J
University Department of Haematology, Royal Liverpool Hospital, United Kingdom.
Thromb Res. 1987 Jul 1;47(1):77-84. doi: 10.1016/0049-3848(87)90242-8.
Abnormalities of blood coagulation associated with neoplasia may be important in the pathogenesis of tumour spread. Most patients with advanced malignancy have evidence of activated coagulation, but the mechanisms underlying this are unclear. We have examined in vitro monocyte procoagulant activity and compared this to plasma levels of fibrinopeptide A, in 52 patients with clinically localised breast cancer. Patients with localised breast cancer and activated coagulation displayed a strong positive correlation between monocyte procoagulant activity and level of fibrinopeptide A(r = +0.86, p less than 0.001). No such relationship was demonstrated in a smaller number of patients with metastatic breast cancer. It is concluded that monocyte procoagulant activity plays an important role in coagulation activation in patients with localised breast cancer. The implications of this for adjuvant anticoagulant therapy in breast cancer are discussed.
与肿瘤形成相关的血液凝固异常可能在肿瘤扩散的发病机制中起重要作用。大多数晚期恶性肿瘤患者有凝血激活的证据，但其中的潜在机制尚不清楚。我们检测了52例临床确诊为局限性乳腺癌患者的体外单核细胞促凝活性，并将其与血浆纤维蛋白肽A水平进行比较。局限性乳腺癌且有凝血激活的患者，其单核细胞促凝活性与纤维蛋白肽A水平之间呈强正相关（r = +0.86，p < 0.001）。在数量较少的转移性乳腺癌患者中未发现这种关系。得出的结论是，单核细胞促凝活性在局限性乳腺癌患者的凝血激活中起重要作用。本文讨论了这一发现对乳腺癌辅助抗凝治疗的意义。
